On May 12, 2020 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported that advances from its "off-the-shelf" or allogeneic platform at the American Society for Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual meeting which kicked off in virtual format today (Press release, Adaptimmune, MAY 12, 2020, View Source [SID1234557587]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data from a poster summarized recent advances in Adaptimmune’s allogeneic platform demonstrating the production of engineered T-cells, differentiated from human induced pluripotent stem cells (hiPSC) (iT cells). The poster was presented by Garth Hamilton, PhD, a Principal Scientist at Adaptimmune, and Joanna Brewer, PhD, Adaptimmune’s SVP Allogeneic Research. There is a video webcast of this presentation available on the Adaptimmune website: https://bit.ly/2L6jtx5.
"We have clearly demonstrated that we can make T-cells from stem cells. These cells express our engineered SPEAR TCR targeting MAGE-A4 and can kill tumor cells in vitro as effectively as control cells," said Jo Brewer, Adaptimmune’s SVP of Allogeneic Research. "We have also reached a milestone in editing our engineered TCRs into the hiPSC genome to enable successful differentiation. This is one critical element as we plan to build large banks of pluripotent cells for our proprietary differentiation process, to generate functional T-cells expressing our engineered receptors. These are great advances as we prepare for clinical use."
Summary
·Poster Title: Driving ADP-A2M4 SPEAR Expression from an Endogenous Hematopoietic Lineage Promotor for "Off-the-Shelf" T-Cell Therapy for MAGE-A4+ Solid Tumors
·Edited hiPSCs (iT-cells) expressing the ADP-A2M4 TCR can kill cancer targets in vitro
·Data suggests that, like autologous SPEAR T-cells currently in clinical trials, ADP-A2M4 iT-cells have potential to be an efficacious cell therapy
·Ability to promote T-cell receptor expression in iT-cells via genetic knock-in at a defined locus offers an opportunity to produce multiple clonal iPSC banks encoding specific SPEAR TCRs against a range of tumor antigens